Background: Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepidermal blister formation due to tissue-bound and circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. Although eosinophils and their toxic mediators are found abundantly in BP lesions, their role in blister formation has remained unclear. Objective: To investigate the role of eosinophils in the pathogenesis of BP with a specific focus on blister formation and to define conditions inducing dermalepidermal separation (DES). Methods: In an ex vivo human model of BP, normal human skin cryosections were incubated with purified human peripheral blood eosinophils with or without activation in the presence or absence of BP autoantibodies, brefeldin A, diphenyleneiodonium, DNase or blocking F(ab 0 ) 2 fragments to CD16, CD18,
CD32 and CD64. Dermal-epidermal separation was assessed by light microscopy studies and quantified using FIJI software. Results: Following activation with IL-5 and in the presence of BP autoantibodies, eosinophils induced separation along the dermal-epidermal junction of ex vivo skin. Dermal-epidermal separation was significantly reduced by blocking any of the following: Fcc receptor binding (P = 0.048), eosinophil adhesion (P = 0.046), reactive oxygen species (ROS) production (P = 0.002), degranulation (P < 0.0001) or eosinophil extracellular trap (EET) formation (P = 0.048). Conclusions: Our results provide evidence that IL-5-activated eosinophils directly contribute to BP blister formation in the presence of BP autoantibodies. Dermalepidermal separation by IL-5-activated eosinophils depends on adhesion and Fcc receptor activation, requires elevated ROS production and degranulation and involves EET formation. Thus, targeting eosinophils may be a promising therapeutic approach for BP.
Eosinophils are found in a broad spectrum of infectious and noninfectious skin diseases, despite the fact that the skin is devoid of eosinophils under physiologic conditions (1) . Eosinophils are under the control of eosinophil haematopoietins; in particular, interleukin (IL)-5 plays a critical role in regulating the production, differentiation, activation, trafficking and survival of eosinophils (2) . The primary function of eosinophils has been considered to be related to host defence as they can function as potent destructive effector cells (3) . By degranulation of toxic granule proteins or eosinophil extracellular trap (EET) formation, eosinophils are able to kill parasites and bacteria (3) (4) (5) . On the other hand, eosinophils have also been accused of causing tissue damage (3, 6) . According to their cytokine expression, functionally different subpopulations of eosinophils have been identified in skin diseases that might potentially regulate inflammatory responses and/or fibrosis (7) .
Bullous pemphigoid (BP) is the most common autoimmune blistering disease of the skin which is associated with an autoimmune response to BP180 and BP230, two structural components of junctional adhesion complexes, the hemidesmosomes, and subsequent damage to the dermalepidermal junction (DEJ) (8, 9) . Autoreactive B-and T-cell responses against the hemidesmosomal antigens BP180 and BP230 have also been identified (10, 11) . Bullous pemphigoid antigen-specific T cells were shown to produce both Th1 (interferon (IFN)-c) and Th2 (IL-5 and IL-13) cytokines (10) .
Moreover, eosinophil infiltration and dermal-epidermal separation (DES) are typical histological findings in BP. In agreement with the dominant presence of eosinophils, IL-5 and eotaxins were found abundantly in blister fluids (12, 13) . On the other hand, despite the observations of metalloproteinase (MMP)-9 expression by eosinophils at sites of blister formation capable of cleaving the extracellular, collagenous domain of BP180 in vitro (14) , deposition of granule proteins such as major basic protein (MBP), eosinophil-derived neurotoxin and eosinophil cationic protein in BP lesions (15, 16) , and eosinophil extracellular DNA traps (EETs) directed towards the DEJ in BP specimens (17) , a direct contribution of eosinophils to blister formation in BP has not yet been shown. In this study, applying an ex vivo skin model, we aimed at investigating the role of eosinophils in the pathogenesis of BP with a specific focus on blister formation.
Methods

Patient materials
Bullous pemphigoid serum (BPS) samples (n = 30) were obtained from untreated patients with clinically, histopathologically and serologically confirmed BP according to current criteria (18) . Pooled BPS (n = 30) containing both BP180 and BP230 as assessed by ELISA with a mean titre of 106.13 and 39.88 U/ml, respectively, was used (19, 20) . Normal human serum (NHS) samples were obtained from healthy donors without any history of immunosuppression and/or autoimmunity. Eosinophils were collected from the peripheral blood of patients with eosinophilic skin diseases attending the Department of Dermatology as well as from patients with hypereosinophilia diagnosed by the Institute of Pharmacology of the University of Bern (21, 22) . Healthy human foreskin was obtained from routine circumcisions. The study has been approved by the Cantonal Ethics Committee (KEK) Bern. Written informed consent was obtained from all patients or their caregivers, prior to blood and tissue sampling.
Induction and evaluation of DES
Dermal-epidermal separation was analysed using an ex vivo model of DES as previously described (19) ; Life Technologies Europe B.V., Zug, Switzerland), including 10% foetal calf serum to avoid their immediate adherence to the slides, and subsequently added to the sections in the prepared chambers for an incubation of 4 h at 37°C. Tissue sections were then fixed with 3.7% formalin and stained with haematoxylin and eosin (H&E). Dermal-epidermal separation was evaluated by light microscopy studies. The total lengths of DES and DEJ, respectively, were calculated using FIJI (23) . Dermal-epidermal separation was given as a percentage of separation at the DEJ. To assess tissue damage semiquantitatively in the indicated experiments, we scored the extent of skin damage and presence of DES. Each experiment was repeated at least three times to confirm reproducibility.
Isolation of human eosinophils
Peripheral blood eosinophils were isolated by density-gradient centrifugation using the Ficoll-Hypaque technique (Pancoll; Bioswisstec AG, Schaffhausen, Switzerland). The upper phase containing peripheral blood mononuclear cells was removed. The lower phase containing eosinophils, neutrophils and erythrocytes was treated with a lysis solution (1.6 mol/l NH 4 Cl, 100 mmol/l KHCO 3 , 1 mmol/l EDTA) to remove erythrocytes. Isolation of eosinophils was followed by a negative selection procedure with monoclonal antibodies bound in bispecific tetrameric antibody complexes, which were directed against CD2, CD3, CD14, CD16, CD19, CD20, CD36, CD56, CD123, glycophorin A and dextran (EasySep TM ; STEMCELL Technologies, Grenoble, France). The negatively collected eosinophils were analysed by Hemacolor Ò Rapid staining (Merck Millipore, Darmstadt, Germany) and light microscopy. Fractions containing ≥95% mature eosinophils were employed for further experiments.
Activation of eosinophils
In the indicated experiments, eosinophils were stimulated with 25 ng/ml IL-5 (R&D Systems, Minneapolis, MN, USA) or 100 ng/ml IFN-c (R&D Systems) for 20 min at 37°C and/ or with 10 nM complement factor 5a (C5a; Hycult Biotech, Uden, The Netherlands), 100 ng/ml lipopolysaccharides (LPS; Sigma-Aldrich, Buchs, Switzerland), 10 nM N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF, Sigma-Aldrich) or 25 nM phorbol-myristate-acetate (PMA; Calbiochem, Merck&Cie, Darmstadt, Germany) for 15 min at 37°C before adding them to the cryosections.
Blocking adhesion and Fcc receptors (FccRs)
To block adhesion, eosinophils were incubated with 20 lg/ml mouse F(ab 0 ) 2 fragments directed against human CD18
(Ancell Corporation, Bayport, MN, USA) on ice for 45 min.
To block FccR-mediated effects, eosinophils were incubated with 10 lg/ml mouse F(ab 0 ) 2 fragments against CD16, CD32
and CD64 (all from Ancell Corporation) on ice for 45 min. Isotype-matched mouse anti-human F(ab 0 ) 2 fragments (Jackson ImmunoResearch Europe Ltd., Suffolk, UK) served as controls.
Pharmacological inhibition of reactive oxygen species production, degranulation and EET formation
To block reactive oxygen species (ROS) production, eosinophils were incubated with the NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI; Calbiochem, Merck Millipore, Darmstadt, Germany) at increasing concentrations of 1-75 lM for 30 min at 37°C. To block degranulation, eosinophils were incubated with 10 lg/ml brefeldin A (BFA; Sigma-Aldrich Co.) which inhibits vesicular transport and granule emptying (24) for 30 min at 37°C. To degrade the DNA scaffold of EETs (5), 100 U/ml of deoxyribonuclease I (DNase I; Worthington Biochemical Corporation, Lakewood, NJ, USA) was used. All reagents were added to eosinophils prior to their application on skin sections.
To quantify ROS production, 1 lM dihydrorhodamine-123 (DHR; Sigma-Aldrich) was added to activated eosinophils prior to their addition to human skin sections incubated with BPS, NHS, or PBS in a black, glass-bottom 96-well plate (Greiner Bio-One GmbH, Frickenhausen, Germany) (25) . Fluorescence activity of the DHR 123 was measured at 485 nm excitation and 538 nm emission, using a SpectraMax M2 plate reader (Bucher Biotech, Basel, Switzerland) over a time period of 2 h.
Statistical analysis
Data were analysed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA) and presented as means AE SEM. For comparison between treatments, unpaired two-tailed t-tests or one-way ANOVAs followed by Tukey's multiple comparisons tests were applied. P values of ˂0.05 were considered significant.
Results
IL-5-activated eosinophils induce diffuse skin damage with focal DES
To investigate the ability of eosinophils to induce DES, isolated peripheral blood eosinophils at concentrations of 10-40 9 10 6 cells/ml were added to human skin cryosections in the presence of either BPS or NHS. Under these circumstances, eosinophils failed to induce DES (Fig. 1A,B ). In contrast, when the whole leucocyte fraction (30 9 10 6 cells/ml) or isolated neutrophils (30 9 10 6 cells/ml) were used, we observed an extensive DES of 85.2 AE 3.4% and 47.2 AE 7.8%, respectively, in the presence of BPS (Fig. 1A,C,D) , but not NHS.
To evaluate whether eosinophils stimulated with proinflammatory cytokines and mediators are able to induce DES in the ex vivo skin model, eosinophils were activated with IL-5 either alone or together with C5a or LPS before adding them to the cryosections. After a 4-h incubation, IL-5-activated eosinophils caused a diffuse tissue damage with focal separation at the DEJ that was not further enhanced upon additional activation with C5a or LPS (Fig. 1E,F) . As a positive control, we activated eosinophils with PMA, which is known to be a strong, but nonspecific stimulator of eosinophils (5, 26) . Phorbol-myristate-acetate-stimulated eosinophils at concentrations of 20-30 9 10 6 /ml induced massive diffuse skin damage leading to a complete loss of tissue structure (Fig. 1E) . Moreover, we observed extensive extracellular eosinophil granule depositions in areas of tissue damage (Fig. 1G) . Addition of PMA in the absence of eosinophils had no effect (Fig. 1H ). Taken together, these results indicate that eosinophils activated with either IL-5 or PMA induced diffuse skin damage in an autoantibody-independent manner.
Synergistic effect of IL-5 and BP autoantibodies on DES
We next assessed whether BP autoantibodies have an impact on the DES-inducing effect of IL-5-activated eosinophils in our ex vivo skin model. Interestingly, in the presence of BP autoantibodies, we observed a line-up of IL-5-activated eosinophils at the DEJ after 3 h of incubation, where after 4 h, a marked DES was evident affecting 21.2 AE 2.3% of the DEJ ( Fig. 2A-C) . In contrast, IL-5-activated eosinophils in the presence or absence of NHS induced significantly less DES of 9.3 AE 2.8% and 9.8 AE 1.8%, respectively, suggesting that BP autoantibodies enhanced the activating effect of IL-5 on eosinophils to induce DES ( Fig. 2A,D) . Additional stimulation of IL-5-and BPS-activated eosinophils with either IFNc, LPS, or fMLF did not further increase the DES (data not shown).
Eosinophil-induced DES requires FccR and CD18
A critical role for FccR in BP pathogenesis has been demonstrated in an animal model (26) . To investigate the importance of FccRs expressed by eosinophils for the binding of IgG autoantibodies present in BP serum, we used blocking F(ab 0 ) 2 fragments directed against CD16 (FccRIII), CD32 (FccRII) and CD64 (FccRI) to block autoantibody binding on eosinophils. As a control, we used control F(ab 0 ) 2 fragments in these experiments. The blockage of FccRs significantly reduced DES (Fig. 3A-C) , suggesting that BP autoantibodies directly activate eosinophils and/or facilitate attraction of eosinophils to the DEJ in the presence of IL-5 through FccRs. As adhesion has been shown to play a crucial role for eosinophil activation (27) , we tested whether blocking F(ab 0 ) 2 fragments directed against CD18, the common b chain shared by leucocyte integrins, inhibited eosinophilmediated DES. Blockage of CD18 significantly reduced DES, whereas isotype-matched control F(ab 0 ) 2 fragments did not (Fig. 3D-F) . Taken together, binding and adhesion of IL-5-activated eosinophils in the presence of BP autoantibodies appear to be mediated by FccRs and CD18.
ROS production, degranulation and EET formation are involved in DES induction by activated eosinophils
We were next interested in potential molecular mechanisms by which IL-5-and BPS-activated eosinophils induce DES. Reactive oxygen species production has been shown to be required for neutrophil-dependent autoantibody-induced tissue damage in an experimental model of epidermolysis Fig. 4A,D,E) . When the production of ROS by eosinophils co-incubated with skin sections was measured, we observed a rapid increase in ROS production in IL-5-activated eosinophils after 5 min. Reactive oxygen species levels were then relatively constant for about 60 min and subsequently declined. In contrast, PMA-stimulated ROS production continued even after 60 min. Diphenyleneiodonium completely blocked IL-5-induced ROS production. It should be noted that we observed no increase in ROS production of IL-5-activated eosinophils in the presence of BPS (Fig. 4H) . As eosinophil granule deposits have been observed in BP lesions (15, 16) , we aimed to study the role of eosinophil degranulation on DES induction. Blocking degranulation of activated eosinophils by BFA (24, 29, 30) resulted in a significant inhibition of DES (Fig. 4B,F) suggesting a direct contribution of eosinophil granule proteins to blister formation.
In BP lesions, the presence of EETs consisting of a DNA scaffold associated with granule proteins has been observed in close proximity to the DEJ (17) . Furthermore, a destruction of the DNA scaffold by DNase was shown to abolish their functional properties in vitro (4, 5) . To evaluate a possible role of EETs in DES, DNase was added to IL-5-and BPS-activated eosinophils prior to their application on the skin sections. DNase treatment significantly reduced DES induced by activated eosinophils (Fig. 4C,G) .
Discussion
A direct contribution of eosinophils to blister formation in BP has long been suggested because of their characteristic presence in lesional skin, the demonstration of extracellular granule deposits near blisters (15, 16) , EETs directed towards the DEJ (17) , and BP antigen cleavage by the MMP-9 released by eosinophils (14) . So far, animal models have demonstrated a possible pathogenic role of neutrophils, mast cells and macrophages in BP (31) (32) (33) . However, although eosinophils are the dominant cell type recruited to BP lesions, their contribution to blister formation has remained unclear.
In this study, we provide evidence that activated eosinophils directly contribute to blister formation in patients with BP. To induce DES, eosinophils required IL-5 activation. In the presence of BP autoantibodies, DES mediated by IL-5-activated eosinophils was significantly increased. Under these conditions, we also observed an eosinophil lining at the DEJ, but no increased ROS production. Therefore, it is possible that eosinophils bind through their FccRs to the autoantibodies bound to the DEJ that, however, seem to have less importance for eosinophil activation. Dermal-epidermal separation might then be mediated by eosinophil granule proteins which damage the skin either alone or in the context of EET formation (4, 9) .
In agreement with a recent study, we observed that eosinophils activated solely with BP antibodies were not able to induce DES (34) . Noteworthy, also similar to our study, IL-5-activated eosinophils have previously been demonstrated to bind throughout the dermis and not specifically to the basement membrane (35) . Our observations suggest that activated eosinophils may cause diffuse tissue damage with minimal DES, while in the presence of BPS, a line-up of eosinophils occurs at the DEJ, leading to an increased dermal-epidermal splitting.
Bullous pemphigoid antibodies that are present in both serum and tissue of patients with BP (36) have been demonstrated to be essential for subepidermal blister formation in experimental mouse models (37) . Antibodies against the 180-kD BP antigen were bound to the extracellular domain along the plasma membrane, while those against the 230-kD BP antigen were directed to the intracellular domain of the hemidesmosome (38) . These antibodies were mainly of the IgG type and recognized the noncollagenous (NC) site of BP180 (39, 40) . As BPS and purified IgG from the same sera were shown to have identical effects on DES in the ex vivo model and BPS depleted of IgG reactive to NC16A, or F (ab') 2 fragments directed to NC16A failed to induce DES (19), we abstained from a purification and detailed characterization of the BPS in the present study.
The function of an anti-mBP180 IgG depends entirely on its Fc domain, whereas F(ab) 2 of IgG failed to induce BP mediated by neutrophils in an animal model (26) . Human eosinophils have been shown to constitutively express FccRII (CD32) and small amounts of FccRIII (CD16) that were enhanced upon IFN-c stimulation (41, 42) . Our results show that DES in the presence of BPS was highly dependent on functional FccRs on eosinophils. A role of other Fc receptors in eosinophil-mediated blister formation, for example Fce receptor in the subgroup of patients with BP exhibiting IgE autoantibodies to BP180 or BP230 (43, 44) and responding to anti-IgE therapy (45) , seemed unlikely as IgE autoantibodies in BP were shown to activate basophils and mast cells (46) rather than eosinophils that lack functionally active high-affinity IgE receptors (FceRI) (47, 48) .
In lesional BP skin, keratinocytes have been demonstrated to express the intercellular adhesion molecule (ICAM)-1 (49) and thus might attract and bind to eosinophils bearing CD11 and CD18 on their surface (50) . In our ex vivo skin model, blocking CD18 with an anti-CD18 F(ab) 2 fragment inhibited DES mediated by IL-5-and BPS-activated eosinophils, indicating that eosinophil adhesion may also play a role for blister formation in BP.
Eosinophil degranulation with the release of toxic granule proteins subsequently leading to keratinocyte damage and DES has long been suggested as a key pathogenic event in BP (51, 52) . Moreover, the deposition of granule proteins was shown to precede blister formation (15) . Blocking eosinophil degranulation resulted in a significant decrease in DES formation, suggesting that eosinophil granule proteins play an important role for subepidermal blister formation in BP. Eosinophil granule proteins may also occur in association with extracellular DNA, forming so-called EETs (4, 5) . Earlier work suggested that such EETs seem to target the DEJ in BP lesions (17) . The observation that the destruction of the DNA scaffold by DNase significantly reduced DES induced by activated eosinophils points to the possibility that granule proteins present in EETs contribute to the subepidermal splitting in our ex vivo BP model.
NADPH oxidase was shown to be required for autoantibody-dependent tissue damage by neutrophils enabling them to release superoxide in the extracellular space (28, 53) . Compared with neutrophils, eosinophils may form even larger amounts of the NADPH oxidase complex upon activation (54) . Moreover, increased ROS production has been demonstrated to be crucial for EET formation (4, 5) . In this study, we show that pharmacological blocking of ROS production significantly reduced DES induction by activated eosinophils in a concentration-dependent manner. In this experimental setting, however, we were unable to distinguish whether the DPI effect was owing to an inhibition of EET formation, degranulation or extracellular ROS release, or a combination of these possibilities.
Taken together, our study demonstrated that in the presence of BPS, IL-5-activated eosinophils had the capacity to split skin at the DEJ, thus directly contributing to subepidermal blister formation in BP. Dermal-epidermal separation induced by activated eosinophils required eosinophil adhesion and functional FccRs, as well as ROS production and release of granule proteins which appear to mediate tissue damage either alone or in association with EETs. For future study of the role of eosinophils in BP in vivo, the following two approaches seem suitable: developing an animal model for eosinophilic BP or performing a specific targeting of eosinophils in patients with BP (55) .
